Alzheimer’s Pathways: An Investor’s Guide To Biogen, Anavex, And Neurotrope

“Investing in companies taking an anti-amyloid approach are not likely to produce high dividends (literally and figuratively) while investing in companies like Anavex and Neurotrope may eventually pay off. Amyloid oligomers are one of several factors that lead to nitro-oxidative stress in Alzheimer’s disease and they do not reverse that stress. At the recent CTAD conference in Barcelona, Spain a number of companies presented new data regarding their Alzheimer’s drug candidates. Much of the attention focused on Biogen (BIIB), but other companies may be pursuing more fruitful strategies against Alzheimer’s disease. In many cases, results reflect the likely mechanisms of the disease whether its Biogen’s efforts to remove amyloid oligomers, Anavex’s (AVXL) focus on inhibiting intracellular calcium release, or Neurotrope’s (NTRP) hopes founded on the activation of protein kinase C. To a degree, each company’s efforts are linked to the chain of events that leads to the onset and progression of Alzheimer’s disease.”
Read the Full Story at seekingalpha.com